<DOC>
	<DOCNO>NCT00199719</DOCNO>
	<brief_summary>Peg interferon ribavirin currently represent standard approve association treat patient infected hepatitis C virus ( HCV ) . The adjunction amantadine expect gain 10 % sustained virological response ( SVR ) . Unfortunately , 50 % patient remain relapsers virological non responder . The main predictive factor SVR HCV genotype body weight ( BW ) . The impact drug pharmacological property , particularly ribavirin require complementary study . This drug large distribution volume concentration display large inter-individual variability . Two study perform HCV patient find correlation ribavirin dose adjust BW single ribavirin time point serum concentration steady state . The aim study investigate pharmacokinetic-pharmacodynamic relationship ribavirin hepatitis C patient</brief_summary>
	<brief_title>Study Pharmacokinetic Action Amantadine Ribavirin Chronic Hepatitis C. CINAM</brief_title>
	<detailed_description>The study conduct naive patient infect genotype non 2 non 3 administer peginterferon alpha 2-a ( 40KD ) weekly , ribavirin dose adjust BW ( &lt; 75 kg 1000 mg/day , &gt; 75 kg 1200 mg/day ) first three month adjunction amantadine 200 mg daily follow 9 month . Plasma concentration profile ribavirin study first dose ( D0 ) W12 . At period , blood sample collect pre-dose 30 minute , 1 , 1.5 , 2 , 3 , 4 , 6 , 8 , 10 hour post-dosing . Ribavirin concentration measure use liquid chromatography-tandem mass spectrometry ribavirin area concentration-timcurves ( AUC0-10h ) derive plasma concentration profile use linear trapezoidal rule . Virological follow-up perform W2 , W4 , W6 , W8 , W12 , W24 W72 . Early virological response define undetectable viral load W12 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Male female patient &gt; 18 year age &lt; 65 year age GÃ©notype non2 non3 Chronic liver disease consistent chronic hepatitis C infection biopsy ( obtain within past 24 month ) judge local pathologist ( Metavir &gt; A1and &gt; F1 ) Negative urine blood pregnancy test ( woman childbearing potential ) document within 24hour period prior first dose study drug Women ongoing pregnancy breast feed IFN ribavirin therapy previous time Positive test screen antiHAV IgM Ab , HBsAg , antiHBc IgM Ab , antiHIV Ab History evidence medical condition associate chronic liver disease HCV ( e.g. , hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure ) Serum creatinine level &gt; 1.5 time upper limit normal screen History severe psychiatric disease , especially depression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>drug monitoring</keyword>
	<keyword>ribavirin-pharmacokinetic</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>chronic hepatitis C</keyword>
	<keyword>non 2 non 3 genotype</keyword>
</DOC>